SMARCB1 and pancreatic neoplasm: In contrast, BRD9 deletion in SMARCB1-WT cancer lines—PANC1 (Pancreatic cancer) and EW8 (Ewing Sarcoma) yielded no significant effect on cell proliferation (Supplementary Fig. 1B).